SK286057B6 - Liečivo na profylaxiu a ošetrovanie neuropatických bolestí - Google Patents

Liečivo na profylaxiu a ošetrovanie neuropatických bolestí Download PDF

Info

Publication number
SK286057B6
SK286057B6 SK292-2002A SK2922002A SK286057B6 SK 286057 B6 SK286057 B6 SK 286057B6 SK 2922002 A SK2922002 A SK 2922002A SK 286057 B6 SK286057 B6 SK 286057B6
Authority
SK
Slovakia
Prior art keywords
pain
neuropathic pain
treatment
hyperalgesia
medicament
Prior art date
Application number
SK292-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK2922002A3 (en
Inventor
Chris Rundfeldt
Reni Bartsch
Angelika Rostock
Christine Tober
Rita Dost
Original Assignee
Valeant Pharmaceuticals North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals North America filed Critical Valeant Pharmaceuticals North America
Publication of SK2922002A3 publication Critical patent/SK2922002A3/sk
Publication of SK286057B6 publication Critical patent/SK286057B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK292-2002A 1999-09-27 2000-09-22 Liečivo na profylaxiu a ošetrovanie neuropatických bolestí SK286057B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain
PCT/EP2000/009284 WO2001022953A2 (de) 1999-09-27 2000-09-22 Verwendung von retigabin zur behandlung von neuropathischen schmerzen

Publications (2)

Publication Number Publication Date
SK2922002A3 SK2922002A3 (en) 2002-08-06
SK286057B6 true SK286057B6 (sk) 2008-02-05

Family

ID=23606675

Family Applications (1)

Application Number Title Priority Date Filing Date
SK292-2002A SK286057B6 (sk) 1999-09-27 2000-09-22 Liečivo na profylaxiu a ošetrovanie neuropatických bolestí

Country Status (35)

Country Link
US (1) US6117900A (uk)
EP (1) EP1223927B1 (uk)
JP (1) JP2003510273A (uk)
KR (1) KR100730829B1 (uk)
CN (2) CN100522155C (uk)
AR (1) AR026163A1 (uk)
AT (1) ATE288748T1 (uk)
AU (1) AU777764B2 (uk)
BG (1) BG65795B1 (uk)
BR (1) BR0014293A (uk)
CA (2) CA2659048A1 (uk)
CZ (1) CZ295980B6 (uk)
DE (1) DE50009504D1 (uk)
DK (1) DK1223927T3 (uk)
EE (1) EE05073B1 (uk)
ES (1) ES2237461T3 (uk)
HK (1) HK1052471A1 (uk)
HR (1) HRP20020234A2 (uk)
HU (1) HUP0202853A3 (uk)
IL (3) IL148309A0 (uk)
IS (1) IS6303A (uk)
MX (1) MXPA02003179A (uk)
NO (1) NO329744B1 (uk)
NZ (1) NZ517616A (uk)
PL (1) PL200847B1 (uk)
PT (1) PT1223927E (uk)
RS (1) RS50091B (uk)
RU (1) RU2264813C2 (uk)
SI (1) SI1223927T1 (uk)
SK (1) SK286057B6 (uk)
TR (1) TR200200706T2 (uk)
TW (1) TWI257304B (uk)
UA (1) UA72550C2 (uk)
WO (1) WO2001022953A2 (uk)
ZA (1) ZA200202449B (uk)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411564A1 (en) * 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
IL157313A0 (en) 2001-02-20 2004-02-19 Bristol Myers Squibb Co Modulators of kcnq potassium channels and uses thereof
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
AU2003268424A1 (en) * 2002-09-05 2004-03-29 Scios Inc. Treatment of pain by inhibition of p38 map kinase
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
US7368472B2 (en) * 2002-12-27 2008-05-06 H. Lundbeck A/S 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
CN100448867C (zh) * 2002-12-27 2009-01-07 H·隆德贝克有限公司 用于治疗中枢神经系统疾病的1,2,4-三氨基苯衍生物
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7812020B2 (en) 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
NZ590885A (en) * 2008-07-18 2013-01-25 Valeant Pharmaceuticals Int A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
WO2019014547A1 (en) 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
PL353393A1 (en) 2003-11-17
DK1223927T3 (da) 2005-04-11
NO20021418L (no) 2002-03-21
ATE288748T1 (de) 2005-02-15
WO2001022953A2 (de) 2001-04-05
AR026163A1 (es) 2003-01-29
EP1223927A2 (de) 2002-07-24
AU7906100A (en) 2001-04-30
IL148309A0 (en) 2002-09-12
HUP0202853A3 (en) 2003-10-28
BR0014293A (pt) 2002-05-21
IL187030A0 (en) 2008-02-09
DE50009504D1 (de) 2005-03-17
CN100522155C (zh) 2009-08-05
IL148309A (en) 2007-12-03
WO2001022953A3 (de) 2002-05-23
ES2237461T3 (es) 2005-08-01
HUP0202853A2 (hu) 2002-12-28
RU2264813C2 (ru) 2005-11-27
TR200200706T2 (tr) 2002-10-21
SK2922002A3 (en) 2002-08-06
MXPA02003179A (es) 2003-08-20
HRP20020234A2 (en) 2003-06-30
YU20302A (sh) 2005-03-15
CA2384504C (en) 2009-05-26
AU777764B2 (en) 2004-10-28
SI1223927T1 (uk) 2005-08-31
EE200200145A (et) 2003-04-15
HK1052471A1 (zh) 2003-09-19
RU2002109240A (ru) 2004-01-10
US6117900A (en) 2000-09-12
RS50091B (sr) 2009-01-22
NZ517616A (en) 2002-12-20
CZ295980B6 (cs) 2005-12-14
BG65795B1 (bg) 2009-12-31
CA2659048A1 (en) 2001-04-05
KR100730829B1 (ko) 2007-06-20
NO20021418D0 (no) 2002-03-21
CA2384504A1 (en) 2001-04-05
CN101444498A (zh) 2009-06-03
PT1223927E (pt) 2005-06-30
EE05073B1 (et) 2008-10-15
CZ2002989A3 (cs) 2002-08-14
JP2003510273A (ja) 2003-03-18
BG106450A (en) 2002-09-30
TWI257304B (en) 2006-07-01
UA72550C2 (en) 2005-03-15
IL187030A (en) 2011-06-30
KR20020042691A (ko) 2002-06-05
IS6303A (is) 2002-03-18
NO329744B1 (no) 2010-12-13
PL200847B1 (pl) 2009-02-27
ZA200202449B (en) 2003-03-26
CN1409632A (zh) 2003-04-09
EP1223927B1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
SK286057B6 (sk) Liečivo na profylaxiu a ošetrovanie neuropatických bolestí
Devor et al. Reversible analgesia, atonia, and loss of consciousness on bilateral intracerebral microinjection of pentobarbital
Bandler Jr Cholinergic synapses in the lateral hypothalamus for the control of predatory aggression in the rat
Manabe et al. Effects of lidocaine on salicylate-induced discharge of neurons in the inferior colliculus of the guinea pig
Kirillova et al. Effect of local and intravenous lidocaine on ongoing activity in injured afferent nerve fibers
Miller et al. Identification of a median thalamic system regulating seizures and arousal
SK287714B6 (en) Use of amino acid derivative for the preparation of pharmaceutical compositions for treating phantom pain or diabetic neuropathic pain
EP1893193A2 (en) Use of brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
Wasterlain et al. The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus
DE60103546T2 (de) Verwendung von carbamat verbindungen zur vorbeugung oder behandlung von neuropathischen- , cluster- und migräneartigen kopfschmerzen
US20180221380A1 (en) Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia
PT626851E (pt) Utilizacao de 3,5-diamino-6-(2,3-diclorofenil)-1,2,4-triazina para a preparacao de um medicamento para o tratamento de certos tipos de dor e edema
Luo et al. Effects of intrathecal local anesthetics on spinal excitability and on the development of autotomy
Grossman Modification of emotional behavior by intracranial administration of chemicals
US20070066638A1 (en) Ryanodine receptor blockers for treating pain
Hernández et al. Posttraumatic epilepsy and neurorehabilitation
US2775539A (en) Process of and compositions for combating epileptic seizures with atrolactamide
Garg et al. Treatment of pain, paresthesias and paroxysmal disorders in multiple sclerosis
US20150259302A1 (en) Indication of naphtho[2,3-f]quinoxaline-7,12-dione compound in alleviating pain
Kanner I. OVERVIEW

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120922